Different characteristics of the tumor immune microenvironment among subtypes of salivary gland cancer

被引：0

作者：

Nagatani, Yoshiaki ^{[1
]}

Kiyota, Naomi ^{[1
,2
]}

Imamura, Yoshinori ^{[1
]}

Koyama, Taiji ^{[1
]}

Funakoshi, Yohei ^{[1
]}

Komatsu, Masato ^{[3
]}

Itoh, Tomoo ^{[3
]}

Teshima, Masanori ^{[4
]}

Nibu, Ken-Ichi ^{[4
]}

Sakai, Kazuko ^{[5
]}

Nishio, Kazuto ^{[5
]}

Shimomura, Manami ^{[6
]}

Nakatsura, Tetsuya ^{[6
]}

Ikarashi, Daiki ^{[6
]}

Nakayama, Takayuki ^{[6
]}

Kitano, Shigehisa ^{[7
]}

Minami, Hironobu ^{[1
,2
]}

机构：

[1] Kobe Univ, Grad Sch Med, Dept Med Oncol & Hematol, Kobe, Japan

[2] Kobe Univ Hosp Canc Ctr, Kobe, Japan

[3] Kobe Univ, Grad Sch Med, Dept Diagnost Pathol, Kobe, Japan

[4] Kobe Univ, Grad Sch Med, Dept Otorhinolaryngol Head & Neck Surg, Kobe, Japan

[5] Kindai Univ, Fac Med, Dept Genome Biol, Sayama, Japan

[6] Exploratory Oncol Res & Clin Trial Ctr, Natl Canc Ctr, Div Canc Immunotherapy Kashiwa, Kashiwa, Japan

[7] Canc Inst Hosp Japanese Fdn Canc Res, Ctr Adv Med Dev, Div Canc Immunotherapy Dev, Tokyo, Japan

来源：

ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY | 2024年 / 20卷 / 06期

关键词：

immune checkpoint inhibitor; multiplexed fluorescent immunohistochemistry; salivary gland cancer; tumor immune microenvironment; tumor mutation burden; SQUAMOUS-CELL CARCINOMA; PHASE-II; COMBINED NIVOLUMAB; PD-1; BLOCKADE; PATIENTS PTS; OPEN-LABEL; IPILIMUMAB; HEAD; CHEMOTHERAPY; EXPRESSION;

D O I：

10.1111/ajco.14108

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

AimAlthough immune checkpoint inhibitors (ICPi) for salivary gland cancer (SGC) have been investigated in clinical trials, details of the tumor immune microenvironment (TIME) remain unclear. This research aimed to elucidate the TIME of SGC and its relationship with tumor mutation burden (TMB) and to explore the rationale for the applicability of ICPi.Materials and methodsWe selected five pathological types, namely adenoid cystic carcinoma (ACC); adenocarcinoma, not otherwise specified (ANOS); salivary duct carcinoma (SDC); and low/high-grade mucoepidermoid carcinoma (MEClow/high). We investigated the TIME and TMB of each pathological type. TIME was evaluated by multiplexed fluorescent immunohistochemistry. TMB was measured by next-generation sequencing.ResultsACC and MEChigh showed the lowest and highest infiltration of immune effector and suppressor cells in both tumor and stroma. ANOS, SDC, and MEClow showed modest infiltration of immune effector cells in tumors. Correlation analysis showed a positive correlation between CD3+CD8+ T cells in tumor and TMB (r = 0.647). CD3+CD8+ T cells in tumors showed a positive correlation with programmed cell death-ligand 1 expression in tumor cells (r = 0.513) and a weak positive correlation with CD3+CD4+Foxp3+ cells in tumors (r = 0.399). However, no correlation was observed between CD3+CD8+ T cells and CD204+ cells in tumors (r = -0.049).ConclusionThe TIME of ACC was the so-called immune desert type, which may explain the mechanisms of the poor response to ICPi in previous clinical trials. On the other hand, MEChigh was the immune-inflamed type, and this may support the rationale of ICPi for this pathological subtype. The tumor immune microenvironment of adenoid cystic carcinoma was the so-called immune desert type, which may explain the poor response of this type to immune checkpoint inhibitors. In contrast, high-grade mucoepidermoid carcinoma was of the immune inflamed type, which may support the application of immune checkpoint inhibitors to this pathological subtype. image

引用

页码：779 / 788

页数：10